An observational study in Diabetes Mellitus, Type 1, sponsored by DCB Research AG. Recruiting at 1 site in Switzerland. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2025-12-03.
Sponsored by DCB Research AG · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 70 studies in Diabetes Mellitus, Type 1 with a site in Switzerland — 9 open to participants now, 10 under way, 4 of them phase 3. Diabetes Mellitus, Type 1 · Switzerland.
Among the 70 studies in Diabetes Mellitus, Type 1 with a site in Switzerland, this one is the 5th largest by planned enrollment of the 18 observational ones that give a count, is one of 4 that started in 2025, is one of 18 observational ones, and was the 63rd registered.
3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →9 of the 70 studies in Diabetes Mellitus, Type 1 with a site in Switzerland are open now. Recruiting first, the newest first:
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Switzerland, Canada
Ages 18+
Sanofi · Sites in Switzerland, United States, Argentina and 17 more countries
Ages 1–25
University of Bern · Sites in Switzerland
Ages 18–65
Pediatric Clinical Research Platform · Sites in Switzerland
Ages 0–25 · Healthy volunteers
University Hospital, Geneva · Sites in Switzerland
Ages 2–18 · Healthy volunteers
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.
This study: 18 Years to 40 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
70 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 13 · Phase 3 16
First in 1997; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 350 is above the median of 125 across 791 observational studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 29 across the 52 interventional studies, 73 across the 18 observational. Of the 55 that completed or were terminated, 6 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 70 have an industry lead sponsor. The 10 most frequent:
DCB Research AG is the lead sponsor of 6 studies on the registry; 2 are open to participants now.
DCB Research AG has 3 studies filed under Diabetes Mellitus, Type 1 — fewer than ten, so there is no comparison to draw.
3 of the studies in Diabetes Mellitus, Type 1 with a site in Switzerland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05594706University Hospital, GenevaAnhydroglucitol in Children With Type 1 Diabetes | 2026-12-31 |
| NCT05791201Vertex Pharmaceuticals IncorporatedA Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes | 2027-03-12 |
| NCT06282055DCB Research AGTrajectories in Insulin Sensitivity Across MEnstrual cycleS in Women With Type 1 Diabetes | 2027-09-15 |
Add all 3 to your calendar (.ics) → With an account.
Among the 70 studies in Diabetes Mellitus, Type 1 with a site in Switzerland, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Standardized longitudinal data collection of diabetes management relevant factors in women with T1D (insulin requirements, glucose variability, nutritional information, and menstrual cycle information) to identify categories of cycle trajectories.
People with menstrual cycles living with Type 1 Diabetes who are using a hybrid closed-loop system.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Women living with T1D who are willing to share their diabetes management and menstrual cycle data.
Other: No intervention
Observational prospective longitudinal data collection
Identify clusters in trajectories across the menstrual cycle
1. Insulin sensitivity across the menstrual cycle/menstrual cycle phases (see Table 1 for definitions relevant to the clinical endpoints). 2. Glycemia measures across the menstrual cycle/menstrual cycle phases: * Percentage in Time In Range (TIR), Rime In Tight Range (TITR), Time Below Range (TBR), Time Above Range (TAR), Coefficient of Variation (CV) * Mean glucose and mean fasted glucose * High and Low Blood Glucose Index (HBGI and LBGI) and Glucose Management Indicator (GMI) 3. Insulin administration measures across the menstrual cycle/menstrual cycle phases: * Basal and bolus insulin dosage * Total daily dose (TDD) * Basal/bolus ratio
Time frame: 6 months
To quantify and classify the techniques used for manual insulin adjustments, comparing their utilization and effectiveness.
2\. Manual Insulin Adjustment Techniques: * Frequency and classification (e.g., timing, magnitude) of manual insulin adjustments. * Impact of adjustment techniques on glycemic outcomes.
Time frame: 6 months
To quantify differences in clusters in insulin sensitivity, glycemic metrics and insulin administration across different phases of the menstrual cycle
Identification and characterization of distinct clusters in glycemic metrics, insulin administration and insulin sensitivity representing unique patterns across distinct menstrual cycle phases (early follicular phase, late follicular phase, peri-ovulation, early luteal, mid luteal and late luteal phase)
Time frame: 6 months
To identify predictive factors that correlate individual participants and menstrual cycles with specific insulin sensitivity and clinical endpoints.
Predictive Factors: o Identification of demographic, clinical, or physiological predictors (e.g., premenstrual cycle syndrome (PMS) score or age group) that significantly correlate with primary outcomes.
Time frame: 6 months
Plan to share: Undecided — We plan to share the data but haven't specified the details yet.
No publications or documents are linked to this record.
Started Nov 2025 (actual). Primary completion is estimated for Sep 2027, 21 months after the start.
Of 248 non-industry observational studies under Diabetes Mellitus, Type 1, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 78. This study's planned 21 months is below that.
Counting every sponsor, half of 298 studies reached it within 28 months; a quarter within 12 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
DCB Research AG